中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
9期
802-807
,共6页
朱志娟%陈健%余梦霞%陈菲菲%陈志妹%楼基余%佟红艳%黄健%钱文斌
硃誌娟%陳健%餘夢霞%陳菲菲%陳誌妹%樓基餘%佟紅豔%黃健%錢文斌
주지연%진건%여몽하%진비비%진지매%루기여%동홍염%황건%전문빈
基因,TET2%基因表达%白血病,髓样,急性%预后
基因,TET2%基因錶達%白血病,髓樣,急性%預後
기인,TET2%기인표체%백혈병,수양,급성%예후
Gene,TET2%Gene expression%Leukemia,myeloid,acute%Prognosis
目的 探讨TET2基因表达水平在成人正常核型急性髓系白血病(CN-AML)中的临床意义.方法 实时定量PCR方法检测157例成人CN-AML患者TET2基因表达水平,并分析其临床意义.结果 CN-AML患者骨髓单个核细胞和骨髓CD34+细胞中TET2基因表达中位值均低于正常对照[7.29(3.41～9.99)对8.13(6.68～9.04),6.02(5.64～6.54)对6.48(5.97～7.12),P值分别为0.026和0.034).CN-AML患者初发时TET2基因表达水平[7.32(6.11～8.41)]明显低于其完全缓解时[8.39(7.76～8.79)](P＜0.01).在157例CN-AML患者中,TET2基因低表达组18个月的总生存(OS)率[(32.7±5.9)％]明显低于高表达组[(48.6±6.9)％](P=0.041).在预后多因素分析中,TET2基因低表达是CN-AML患者OS和无事件生存的独立危险因素[风险比(HR)分别为2.032 (95％CI 1.272～3.247)和1.532 (95％CI1.014～2.314),P值分别为0.003和0.043].结论 CN-AML患者TET2基因表达水平低于正常对照,TET2基因低表达的CN-AML患者预后较差,TET2基因低表达可作为CN-AML患者预后不良指标.
目的 探討TET2基因錶達水平在成人正常覈型急性髓繫白血病(CN-AML)中的臨床意義.方法 實時定量PCR方法檢測157例成人CN-AML患者TET2基因錶達水平,併分析其臨床意義.結果 CN-AML患者骨髓單箇覈細胞和骨髓CD34+細胞中TET2基因錶達中位值均低于正常對照[7.29(3.41～9.99)對8.13(6.68～9.04),6.02(5.64～6.54)對6.48(5.97～7.12),P值分彆為0.026和0.034).CN-AML患者初髮時TET2基因錶達水平[7.32(6.11～8.41)]明顯低于其完全緩解時[8.39(7.76～8.79)](P＜0.01).在157例CN-AML患者中,TET2基因低錶達組18箇月的總生存(OS)率[(32.7±5.9)％]明顯低于高錶達組[(48.6±6.9)％](P=0.041).在預後多因素分析中,TET2基因低錶達是CN-AML患者OS和無事件生存的獨立危險因素[風險比(HR)分彆為2.032 (95％CI 1.272～3.247)和1.532 (95％CI1.014～2.314),P值分彆為0.003和0.043].結論 CN-AML患者TET2基因錶達水平低于正常對照,TET2基因低錶達的CN-AML患者預後較差,TET2基因低錶達可作為CN-AML患者預後不良指標.
목적 탐토TET2기인표체수평재성인정상핵형급성수계백혈병(CN-AML)중적림상의의.방법 실시정량PCR방법검측157례성인CN-AML환자TET2기인표체수평,병분석기림상의의.결과 CN-AML환자골수단개핵세포화골수CD34+세포중TET2기인표체중위치균저우정상대조[7.29(3.41～9.99)대8.13(6.68～9.04),6.02(5.64～6.54)대6.48(5.97～7.12),P치분별위0.026화0.034).CN-AML환자초발시TET2기인표체수평[7.32(6.11～8.41)]명현저우기완전완해시[8.39(7.76～8.79)](P＜0.01).재157례CN-AML환자중,TET2기인저표체조18개월적총생존(OS)솔[(32.7±5.9)％]명현저우고표체조[(48.6±6.9)％](P=0.041).재예후다인소분석중,TET2기인저표체시CN-AML환자OS화무사건생존적독립위험인소[풍험비(HR)분별위2.032 (95％CI 1.272～3.247)화1.532 (95％CI1.014～2.314),P치분별위0.003화0.043].결론 CN-AML환자TET2기인표체수평저우정상대조,TET2기인저표체적CN-AML환자예후교차,TET2기인저표체가작위CN-AML환자예후불량지표.
Objective To explore the clinical significance of ten-eleven-translocationmethylcytosine dioxygenase 2 (TET2) mRNA expression levels in adult acute myeloid leukemia patientswith normal cytogenetics (CN-AML).Methods Expression levels of TET2 mRNA were measured byreal-time PCR in 157 adult CN-AML,and its clinical impact in CN-AML was evaluated as well.ResultsTET2 gene expression levels from bone marrow mononuclear cells (BMMNCs) [7.29 (3.41-9.99)] andCD34+ cells [6.02 (5.64-6.54)] in CN-AML were significantly lower than those [BMMNCs:8.13 (6.68-9.04),P=0.026; CD34+ cells:6.48 (5.97-7.12),P=0.034] in healthy control.And TET2 mRNA level atdiagnosis [7.32 (6.11-8.41)] was obviously lower than that at complete remission [8.39 (7.76-8.79),P＜0.01].CN-AML patients with lower levels of TET2 mRNA showed worse survival rate [(32.7±5.9)％] at18-month than those with higher levels [(48.6±6.9)％,P=0.041].In multivariate analysis,lower level ofTET2 mRNA was an independent prognostic factor for OS [hazard ratio (HR) 2.032,95％ confidenceinterval (CI) 1.272-3.247,P=0.003]and event-free survival [HR 1.532,95％ CI 1.014-2.314,P=0.043].Conclusions The level of TET2 mRNA is significantly lower in patients with CN-AML and it is anindependent negative prognostic factor.TET2 could be an important factor for the molecular-based riskstratification in CN-AML.
